+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy, safety, and tolerability of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in adults with chronic kidney disease CKD Stage 3b and 4, who have an estimated glomerular filtration rate eGFR between 15 and less than 45 mLmin1.73 m2. This Phase III study focuses on a population with high unmet medical needs and increased risk of CKD progression, often excluded from other trials. The main goal is to see if the combination reduces cardiovascular death, kidney failure, and heart failure events. Participants will be randomly assigned to one of two groups one receiving a daily capsule containing balcinrenone 15 mg and dapagliflozin 10 mg plus a placebo tablet matching dapagliflozin, and the other receiving a dapagliflozin 10 mg tablet plus a placebo capsule matching balcinrenonedapagliflozin. All treatments are taken orally once daily alongside standard of care therapy. The study is conducted globally at approximately 550 sites in about 30 countries. During the study, participants will be monitored for up to 46 months to track outcomes such as cardiovascular death, kidney failure, and decline in kidney function measured by eGFR. Researchers will also assess changes in urinary albumin to creatinine ratio and overall safety and tolerability. Participants will have regular visits for assessments including laboratory tests and clinical evaluations to measure these outcomes and monitor health status throughout the study.

Age: 18Years - 99YearsAll GendersPhase 3
478 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
P

Actively Recruiting

Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.

Age: 18Years +All GendersPhase 3
715 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.

Age: 5Years - 11YearsAll GendersPhase 3
147 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.

Age: 40Years - 80YearsAll GendersPhase 3
305 locations
P

Actively Recruiting

Researchers are evaluating the effects of tozorakimab, a drug given by injection under the skin, in adults with uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids. This phase IIb study is designed to find the right dose and assess how safe and effective tozorakimab is for reducing severe asthma attacks over a period of 26 to 52 weeks. Participants will be randomly assigned to receive one of two doses of tozorakimab or a placebo, all given subcutaneously. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The treatment period lasts up to 52 weeks with regular monitoring. The study will measure asthma exacerbation rates, lung function changes, asthma control, quality of life, and drug levels in the blood. During the trial, participants will complete daily asthma diaries to track symptoms and medication use, and attend visits for lung function tests, questionnaires, and blood samples. Safety and antibody responses to the drug will be monitored throughout. Participation lasts up to about one year, including screening and treatment, with regular visits to assess health and response to the study drug.

Age: 18Years - 75YearsAll GendersPhase 2
223 locations
I

Actively Recruiting

Healthy Volunteer

Researchers are studying how different partially hydrolyzed, whey-based infant formulas affect growth and digestive comfort in healthy full-term infants. This is a randomized, controlled trial comparing two experimental formulas made with hydrolyzed protein to a control formula containing intact protein. The study aims to understand how these formulas influence infant growth over the first four months and their gastrointestinal tolerance. Participants will receive one of three infant formulas a control formula with intact protein, Experimental Formula 1 with hydrolyzed protein, or Experimental Formula 2 also with hydrolyzed protein but produced using a different milk protein base. These formulas differ slightly in protein content and processing. The study follows infants from enrollment until they reach 4 months of age to assess growth differences and equivalence, while also monitoring for tolerance. During the study, researchers will monitor participants growth through measurements like weight, length, and head circumference at various ages up to 6 months. They will also assess gastrointestinal tolerance, stool patterns, allergy symptoms, and dietary intake through scheduled visits. The primary outcomes focus on growth during the first 4 months. This trial includes regular assessments to track infants health, development, and any allergic or digestive symptoms during their first year.

Age: 0Days - 28DaysAll GendersPhase Not Applicable
5 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effects of a dietary supplement on the gut microbiome of healthy term infants aged around 5 months. The study is a double-blind, randomized, placebo-controlled nutritional trial designed to compare changes in the fecal microbiome composition between infants receiving the supplement and those receiving a placebo over a 5-month period. The goal is to understand how the supplement influences gut health and related biological markers. Participants are randomly assigned to one of two groups an experimental group receiving the dietary supplement and a control group receiving a placebo, both provided in powder form. Parents dissolve the powder in lukewarm formula or breastmilk and feed it to their infants using a supplied feeding beaker. The intervention lasts for 5 months, with the supplement or placebo given daily during this time. Throughout the study, infants undergo regular assessments including stool sample collection for microbiome and metabolic analysis, blood tests for immune health, measurements of growth such as weight and length, bone quality evaluation, and monitoring of gastrointestinal symptoms and infant illness. Dietary intake and neurodevelopment are also tracked using questionnaires and standardized tools. The trial lasts for 5 months of intervention with multiple clinic visits for data collection and monitoring.

Age: 19Weeks - 21WeeksAll GendersPhase Not Applicable
2 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of JNJ-90301900 NBTXR3 activated by radiotherapy with or without cetuximab compared to radiotherapy with or without cetuximab alone in elderly participants with locally advanced head and neck squamous cell carcinoma LA-HNSCC who are not eligible for platinum-based chemotherapy. This Phase 3 pivotal trial includes participants aged 60 and older who have not received prior treatment and meet specific clinical and health criteria. Participants are randomly assigned to one of two groups one group receives JNJ-90301900 NBTXR3 as an intratumoral or intranodal injection at a dose of 33% of the gross tumor volume, activated by investigators choice of radiotherapy alone or combined with cetuximab. The other group receives radiotherapy alone or radiotherapy combined with cetuximab. Radiotherapy is delivered as intensity-modulated radiation therapy IMRT at 70 Gray in 35 fractions over 7 weeks. During the study, participants undergo assessments to monitor progression-free survival, overall survival, local and distant cancer control, quality of life using specific questionnaires, safety through adverse event monitoring, and response rates. These evaluations occur up to 48 months following the first randomized participant. The trial is open-label with no masking, and participation lasts until study completion, with safety and efficacy continuously monitored.

Age: 60Years +All GendersPhase 3
196 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations

1-10 of 11

1